Dr. Philip Koi

Dr. Philip Koi
Dr. Koi’s areas of clinical specialty include urologic cancer, kidney stones, prostatic diseases, female urology (including incontinence), da Vinci Robot Surgical System, no-needle/no-scalpel vasectomy, minimally invasive prostate procedures, and laparoscopic surgery. He joined Arizona Urology Specialists in 2009 and was previously in practice at Canyon State Urology. About Dr. Koi Dr. Koi’s work has been published in numerous scientific publications including: Mason BM, Koi PT, Hafron J, Milhoua P, Hoenig DM. Safety and efficacy of synchronous percutaneous nephrostolithotomy and contralateral ureterorenoscopy for bilateral calculi. J Endourol. 2008 May;22(5):889-93. Milhoua PM, Koi PT, Lowe D, and Ghavamian R. Issue of prostate gland size, laparoscopic radical prostatectomy, and continence revisited. Urology. 2008 Mar;71(3):417-20. Milhoua PM, Koi PT, Hakimi AA, Li M, and Ghavamian R. Laparoscopic nephrectomy for the management of renal medullary carcinoma in a child. J Pediatric Urol. 2008 Feb;4(1):90-2. Sergeyev I, Koi PT, Jacobs SL, Godelman A, Hoenig DM. Outcome of percutaneous surgery stratified according to body mass index and kidney stone size. Surg Laparosc Endosc Percutan Tech. 2007 Jun;17(3):179-83. Koi P, Milhoua PM, Monrose V, Disanto ME, Melman A. Expression of Myosin Isoforms in the Smooth Muscle of Human Corpus Cavernosum. Int J Impot Res. 2007 Jan-Feb;19(1):62-8. Milhoua PM, Knoll A, Koi P, Hoenig D, and Ghavamian R. Laparoscopic pelvic nephrectomy in preparation for renal transplantation. JSLS 2006 Oct-Dec;10(4):538-40. Dr. Koi grew up in Southern California. He enjoys spending time with his wife and three children. Dr. Koi is an avid football and basketball fan.
Medical School:

Tufts University


Albert Einstein College of Medicine


University of California Los Angeles Los Angeles, CA

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only